(Total Views: 524)
Posted On: 01/05/2025 2:00:47 PM
Post# of 153903
Re: KenChowder #148989
Just wanted to add additional content to my previous post. Dr. J mentioned in the December Letter to Shareholders that he has submitted the results of the preclinical study to the MASH TAG conference board for review and acceptance:
"First, CytoDyn previously announced exciting results from an initial preclinical study with SMC Laboratories evaluating leronlimab in the treatment of a mouse model of MASH. The results from this preliminary study demonstrated that high dose leronlimab was significantly better at reversing liver fibrosis compared to an IgG 4 isotype control and demonstrated a trend toward better fibrosis reversal compared to Resmetirom. The final results from that study have now also demonstrated that leronlimab (both high and low dose) was significantly better than Resmetirom at reversal of fat deposition (steatosis) in the liver. These exciting findings have been submitted as a late breaker abstract to the MASH TAG conference and, if accepted, will be presented at the meeting in January ."
"First, CytoDyn previously announced exciting results from an initial preclinical study with SMC Laboratories evaluating leronlimab in the treatment of a mouse model of MASH. The results from this preliminary study demonstrated that high dose leronlimab was significantly better at reversing liver fibrosis compared to an IgG 4 isotype control and demonstrated a trend toward better fibrosis reversal compared to Resmetirom. The final results from that study have now also demonstrated that leronlimab (both high and low dose) was significantly better than Resmetirom at reversal of fat deposition (steatosis) in the liver. These exciting findings have been submitted as a late breaker abstract to the MASH TAG conference and, if accepted, will be presented at the meeting in January ."
Quote:
Happy New Year to all. Just saw this and wanted to pass it on.
Dr. Mazen Noureddin was a consultant, advisor, and speaker for CytoDyn two years ago and today he is on the Scientific Advisory Board Committee for MASH-TAG Conference 2025.
Maybe we will have a great update on Monday as to the submission CYDY management made for the Thursday, January 9, 2025 conference.
January 6 is the deadline for submission and they had open spots 2 weeks ago, so maybe we will be presenting (although the current prospectus does not show it).
Expecting big news very soon!
https://www.mashtag.org/_static/documents/202...pectus.pdf
(9)
(0)
